Sign in Subscribe
Cancer

US Non-Small Cell Lung Cancer Market and Competitive Landscape Explored in New Report

Strategic Insights

— 1 min read

A comprehensive market analysis on the US Non-Small Cell Lung Cancer market has been published, providing insights into the pipeline products, epidemiology, market valuations, and forecast, as well as drugs sales and competitive landscape. The report offers a detailed examination of the Non-Small Cell Lung Cancer market, including treatment options, pipeline products, market analysis, and drugs sales. This research will enable monitoring and reporting of national Non-Small Cell Lung Cancer market analysis and sales trends, tracking competitor drugs sales and market share, and synthesizing insights for Non-Small Cell Lung Cancer market and products.

Key Takeaways:

  • The report analyzes the Non-Small Cell Lung Cancer pipeline, including products in clinical trials for treatment, by development phase, pharmacological class, and companies developing the products.
  • The Non-Small Cell Lung Cancer epidemiology section provides the number of patients diagnosed with Non-Small Cell Lung Cancer in the US, including prevalence and forecast to 2027.
  • The report identifies key products marketed and prescribed for Non-Small Cell Lung Cancer in the US, including trade name, molecule name, and company.
  • Non-Small Cell Lung Cancer drugs sales data is provided, offering sales revenues of Non-Small Cell Lung Cancer drugs in the US from 2019 to 2027.
  • The market valuations section finds the market size for Non-Small Cell Lung Cancer drugs in 2021 in the US, with forecast to 2027, and market shares for key Non-Small Cell Lung Cancer drugs.
  • Research scope includes non-small cell lung cancer pipeline products, epidemiology, marketed drugs, market valuations, and forecast.

Statistics:

  • As of 2022, there are 27 Non-Small Cell Lung Cancer Phase 3 clinical trials, 32 Phase 2, and 17 Phase 1 clinical trials in the US.
  • The number of patients diagnosed with Non-Small Cell Lung Cancer in the US is expected to increase from 8,300 in 2021 to 9,300 in 2027.
  • The market size for Non-Small Cell Lung Cancer drugs in 2021 in the US was $2.3 billion, forecast to reach $4.5 billion by 2027.
  • The top 5 companies with the highest share of the Non-Small Cell Lung Cancer drugs market in the US in 2021 include Pfizer, Roche, AstraZeneca, Eli Lilly, and Johnson & Johnson.

Sources:

  • https://www.researchandmarkets.com/r/3uqqx3
  • https://www.businesswire.com/news/home/20220921005575/en/

Read more